Bicalutamide reduces risk of death in prostate cancer

摘要

Treating men with locally advanced prostate cancer with bicalutamide (Casodex) plus radiotherapy reduces the risk of death by more than one-third compared with radiotherapy alone,according to new results from the Early Prostate Cancer Trial,presented at ECCO.